BioVie reports positive NE3107 data in Parkinson's, Alzheimer's, and aging biomarkers

BIOVIE INC.

NE3107+levodopa improved UPDRS Part 3 by 3+ points vs levodopa alone at 2-3 hours (clinically meaningful); 6+ points for patients <70.
NE3107 improved cognition: ADAS-Cog12 +2.2 points (p=0.0173), CDR +0.11 (p=0.0416), ADCOMS +0.07 (p=0.0094) in mild cognitive impairment/mild AD.
NE3107 reduced Horvath DNA methylation SkinBlood clock by 3.3 years (p=0.0021) after 3 months; 19 of 22 patients showed reduction.
BioVie increased Phase 3 AD trial enrollment from 316 to 400; topline results expected before end of Q3 2023.
Company plans to discuss Phase 3 Parkinson's program with FDA and expects to launch Phase 3 trials in 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.